Your browser doesn't support javascript.
loading
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.
Galluzzo, Marco; Marcelli, Lorenzo; Vellucci, Laura; Paganini, Claudia; Maffei, Virginia; Tofani, Lorenzo; Belcastro, Alfredo; Bianchi, Luca; Talamonti, Marina.
Afiliação
  • Galluzzo M; Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
  • Marcelli L; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.
  • Vellucci L; Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
  • Paganini C; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.
  • Maffei V; Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
  • Tofani L; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.
  • Belcastro A; Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
  • Bianchi L; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.
  • Talamonti M; Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Expert Opin Biol Ther ; 23(4): 371-381, 2023 04.
Article em En | MEDLINE | ID: mdl-36971507
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article